

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

Apple Tree Life Sciences, Inc., *et al.*,¹

Debtors.

Chapter 11

Case No. 25-12177 (LSS)

(Jointly Administered)

**RIGMORA BIOTECH INVESTOR ONE LP AND RIGMORA
BIOTECH INVESTOR TWO LP'S WITNESS AND EXHIBIT LIST FOR THE
HEARING ON FEBRUARY 19, 2026 AT 10:00 A.M. (ET)**

Parties in interest Rigmora Biotech Investor One LP, by its general partner Unicorn Biotech Ventures One Ltd, and Rigmora Biotech Investor Two LP, by its general partner Unicorn Biotech Ventures Two Ltd (collectively, the “**LPs**”), by and through their undersigned counsel, hereby file this exhibit list (the “**Witness and Exhibit List**”) identifying the witness testimony and exhibits the LPs may introduce into evidence in connection with the *Debtors’ Motion for an Order (I) Enforcing the Automatic Stay and (II) Imposing Sanctions Against Rigmora* [Docket No. 83]; *Debtors’ Motion for Entry of an Order (I) Approving the Retention and Employment of B. Riley Restructuring Services, LLC to Provide the Debtors with a Chief Restructuring Officer and Additional Staff Effective as of the Petition Date; (II) Designating Perry M. Mandarino as the Chief Restructuring Officer to the Debtors; and (III) Granting Related Relief* [Docket No. 131]; *Debtors’ Application for an Order Authorizing the Retention and Employment of Quinn Emanuel Urquhart & Sullivan, LLP as Co-Counsel for the Debtors Effective as of the Petition Date* [Docket

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors’ service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.



No. 132]; *Debtors' Motion for Entry of Order (I) Authorizing Use of Funds to (A) Fund Portfolio Companies, (B) Pay Management Company Expenses and (C) Pay Chapter 11 Expenses, and (II) Granting Related Relief* [Docket No. 228]; and *Debtors' Motion for Entry of Interim and Final Orders: (A) Authorizing the Debtors to Incur Post-Petition Debt, (B) Granting Super-Priority Administrative Expense Claims, (C) Scheduling a Final Hearing, and (D) Granting Related Relief* [Docket No. 313] at the hearing scheduled on February 19, 2026 at 10:00 a.m. (ET) (the "**Hearing**") before the Honorable Laurie S. Silverstein, at the United States Bankruptcy Court for the District of Delaware, 824 N. Market Street, 6th Floor, Courtroom No. 2, Wilmington, Delaware 19801.

WITNESSES

The LPs designate the following individuals as potential witnesses for the Hearing whose testimony may be presented live and/or through their declarations:

- Mark Phillips KC
- Dr. Ilona Rimm, MD, PhD, CFA
- Dr. Ilya Strebulaev
- Brandon Aebersold

The LPs reserve the right to (a) identify additional witnesses who may testify at the Hearing, (b) cross-examine any witness called by any other party, (c) call additional witnesses for the purposes of rebuttal or impeachment, (d) call any witness identified by another party on their witness list, regardless of whether that party thereafter removes the witness from their list, (e) designate additional deposition testimony, and (f) call any witness necessary for the purpose of authenticating documents or otherwise seeking the admission of documents into evidence.

EXHIBITS

The LPs designate the following exhibits that may be used at the Hearing in connection with the matters to be heard. The LPs reserve the right to ask the Court to take judicial notice of pleadings, transcripts, and/or documents filed in or in connection with the above-captioned cases, to offer rebuttal exhibits, and to modify, supplement, or amend this Witness and Exhibit List at any time prior to or during the Hearing. Designation of any exhibit below does not waive any objections the LPs may have to any exhibit listed on any party's exhibit list or introduced at the hearing.

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
1	First Amended and Restated Limited Partnership Agreement ("LPA")	ATP_00202247
2	LPA Amendment No. 1	ATP_00202344
3	LPA Amendment No. 2	ATP_00202349
4	LPA Amendment No. 3	ATP_00202357
5	LPA Amendment No. 4	ATP_00202362
6	LPA Amendment No. 5	ATP_00202365
7	LPA Amendment No. 6	ATP_00202375
8	LPA Amendment No. 7	ATP_00202378
9	LPA Amendment No. 8	ATP_00202383
10	LPA Amendment No. 9	ATP_00202388
11	LPA Amendment No. 10	ATP_00202407
12	LPA Amendment No. 11	ATP_00202412
13	LPA Amendment No. 12	ATP_00202416

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
14	LPA Amendment No. 13	ATP_00202424
15	LPA Amendment No. 14	ATP_00202429
16	LPA Amendment No. 15	ATP_00202437
17	LPA Amendment No. 16	ATP_00202440
18	LPA Amendment No. 17	ATP_00202444
19	LPA Amendment No. 18	ATP_00202461
20	LPA Amendment No. 19	ATP_00202477
21	LPA Amendment No. 20	ATP_00260368
22	LPA Amendment No. 21	ATP_00202482
23	LPA Amendment No. 22	ATP_00202487
24	Nine Square Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00001600
25	Initial (Opal Biosciences, Inc) Series A Preferred Stock Purchase Agreement	ATP_00001104
26	Nereid Therapeutics Inc. Preferred Stock Purchase Agreement	ATP_00001242
27	Aulos Biosciences, Inc. Series A Preferred Stock Purchase Agreement	ATP_00000678
28	Apertor Pharmaceuticals, Inc Series A Preferred Stock Purchase Agreement	ATP_00000627
29	Marlinspike Therapeutics Inc. Series A Preferred Stock Purchase Agreement	ATP_00334406
30	Evercrisp Biosciences, Inc. Series A Preferred Stock Purchase Agreement	ATP_00334675
31	Red Queen Therapeutics Inc Series A Preferred Stock Purchase Agreement	ATP 00001669
32	Aethon Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00000546
33	Deep Apple Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00088318

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
34	Ascidian Therapeutics, Inc. Series A Preferred Stock Purchase Agreement	ATP_00322023
35	Marengo Therapeutics, Inc. Series B Preferred Stock Purchase Agreement	ATP_00284891
36	Replicate Bioscience, Inc. Series A Preferred Stock Purchase Agreement	ATPBK_00016512
37	Plaintiffs'/Petitioners' Skeleton Argument for PTR	Dkt. 117, Ex. A
38	Correspondence from Cayman Court, Dec. 11, 2025	Dkt. 117, Ex. B
39	Correspondence from Quinn Emanuel to H. Farmer, Dec. 11, 2025	Dkt. 117, Ex. C
40	Correspondence from Walkers to Cayman Court, Dec. 8, 2025	Dkt. 117, Ex. D
41	Cayman PTR Tr., Dec. 17, 2025	Dkt. 117, Ex. E
42	Cayman Judgment, Dec. 22, 2025	Dkt. 117, Ex. F
43	In the Matters of Soundview Elite Ltd, Soundview Premium Ltd, Soundview Star Ltd. [2013] CIGC J1213-1	Dkt. 117, Ex. G
44	Chancery Post-trial Opinion	Dkt. 117, Ex. H
45	Kuwait Ports Authority v Port Link GP Ltd [2023] (1) CILR 50	Dkt. 225, Ex. F
46	Chancery Court Pre-Trial Order, Sept. 5, 2025	Dkt. 225, Ex. G
47	Excerpt of Quinn Emanuel Second Day Hr'g PowerPoint	Dkt. 225, Ex. M
48	<i>Kuwait Ports Authority v Williams</i> [2024] UKPC 32	Dkt. 225, Ex. B
49	<i>Re ATP Life Science Ventures LP</i> [2025] CIGC (FSD) 106	Dkt. 225, Ex. C
50	Expert Report of Michael Bloch KC, Aug. 15, 2025	Dkt. 225, Ex. D
51	Cayman Amended Winding-Up Petition, Nov. 21, 2025	Dkt. 225, Ex. H
52	U.S. Trustee Program Manual and Policies: Vol. 3 Chapter 11 Case Administration	Dkt. 225, Ex. N
53	Seth L. Harrison, M.D., ATP – Team Biography	Dkt. 225, Ex. I

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
54	The Future of the USTP's CRO "Protocol," U.S. Dep't of Justice (Sept. 1, 2018), https://www.justice.gov/archives/ust/blog/future-ustps-cro-protocol	Dkt. 225, Ex. O
55	Chancery Court Trial Tr., Oct. 16-17, 2025	Dkt. 225, Ex. K
56	Walkers Letter to Campbells, Sept. 8, 2025	Dkt. 224, Ex. J
57	Chancery Court Complaint	Dkt. 224, Ex. K
58	Email from Quinn Emanuel to Debevoise & Plimpton, January 27, 2026	Dkt. 224, Ex. P
59	Unicorn Biotech Ventures One Ltd v ATP III GP Ltd (No. 4) [2025] CIGC (FSD) 1	Dkt. 224, Ex. Q
60	Unicorn Biotech Ventures One Ltd v ATP III GP Ltd (No. 3) [2026] CIGC (FSD) 5	Dkt. 224, Ex. R
61	Correspondence from Walkers to Campbells, December 3, 2025	Dkt. 224, Ex. S
62	Correspondence from Walkers to Cayman Court, December 8, 2025	Dkt. 224, Ex. T
63	Walkers Letter to Campbells, December 9, 2025	Dkt. 224, Ex. U
64	Opening Report of Dr. Strebulaev	Dkt. 305, Ex. A
65	Chancery Court Defendants' Post-Trial Brief	Dkt. 305, Ex. I
66	Corrected Opening Report of Dr. Rimm, Chancery Court	Dkt. 305, Ex. K
67	March 7, 2024 Correspondence Between S. Harrison and P. Eisenberg	Dkt. 305, Ex. L
68	Opening Report of ATP Expert Rao	Dkt. 305, Ex. P
69	Pluris Valuation of Nereid (Jan. 31, 2025)	Dkt. 305, Ex. Q
70	Pluris Valuation of Marlinspike (Jan. 31, 2025)	Dkt. 305, Ex. R
71	Email from P. Jardine to P. Eisenberg (Oct. 28, 2025)	Dkt. 305, Ex. T
72	Email Correspondence (May 11, 2025)	Dkt. 305, Ex. U
73	April 4, 2025 WhatsApp Exchange Between S. Harrison and A. Batarina	Dkt. 305, Ex. T

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
74	Aug. 20–21, 2024 WhatsApp Exchange Between S. Harrison and M. Ehlers	Dkt. 305, Ex. X
75	Aug. 20, 2024 WhatsApp Exchange Between M. Ehlers and J. Yanchik	Dkt. 305, Ex. V
76	Opening Report of Michael Bloch, KC	Dkt. 305, Ex. Y
77	May 25, 2023 Email Exchange Between W. Engels and Covington & Burling LLP	Dkt. 305, Ex. AA
78	Cayman Hearing Transcript (Oct. 31, 2025)	Dkt. 305, Ex. BB
79	Cayman Islands Powers of Attorney Law (1996 Revision)	Dkt. 305, Ex. DD
80	Chancery Court Final Judgment (Dec. 11, 2025)	Dkt. 305, Ex. FF
81	May 30 Capital Call for Expenses	Dkt. 305, Ex. GG
82	Q2 2025 Quarterly Digest	Dkt. 305, Ex. HH
83	Portfolio Company Descriptions (Jan. 28, 2026)	Dkt. 305, Ex. II
84	Notice of 30(b)(6) Deposition for Red Queen	Dkt. 305, Ex. JJ
85	Debtors' Supplemental Responses & Objections to LPs' Second Funding Motion RFPs and Interrogatories (Feb. 9, 2026)	Dkt. 305, Ex. KK
86	Email Exchange Between S. Harrison and D. Kroin	Dkt. 305, Ex. LL
87	WhatsApp Exchange Between J. Yanchik and A. Bayliffe	Dkt. 305, Ex. MM
88	Email Exchange Between J. Yanchik and M. Ehlers	Dkt. 305, Ex. NN
89	Chancery Plaintiff ATP III GP, Ltd.'s Post-Trial Brief	Dkt. 305, Ex. TT
90	Cayman Winding Up Petition (June 6, 2025)	Dkt. 305, Ex. UU
91	Cayman Amended Winding Up Petition (Nov. 21, 2025)	Dkt. 305, Ex. WW
92	Declaration of Mark Phillips KC	Dkt. 126
93	Interpretation Act (1995 Revision)	Dkt. 126, Ex. B-1

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
94	Exempted Limited Partnership Law (2012 Revision)	Dkt. 126, Ex. B-2
95	Companies Winding Up Rules (2023 Consolidation)	Dkt. 126, Ex. B-3
96	Companies Act (2025 Revision)	Dkt. 126, Ex. B-4
97	Exempted Limited Partnership Act (2025 Revision)	Dkt. 126, Ex. B-5
98	Partnership Act (2025 Revision)	Dkt. 126, Ex. B-6
99	Practice Direction No. 1 of 2018	Dkt. 126, Ex. B-7
100	<i>Harrison v Tennant</i> (1856) 21 Beav 482	Dkt. 126, Ex. B-8
101	<i>I.R.C. v Olive Mill Ltd</i> [1963] 1 WLR 712	Dkt. 126, Ex. B-9
102	<i>Ebrahimi v Westbourne Galleries</i> [1973] AC 360 (HL)	Dkt. 126, Ex. B-10
103	<i>Bristol and West Building Society v Mothew</i> [1998] Ch 1	Dkt. 126, Ex. B-11
104	<i>Hurst v Bryk</i> [2002] 1 AC 185 (HL)	Dkt. 126, Ex. B-12
105	<i>In Re Lehman Brothers International (Europe) (No 2)</i> [2009] EWCA Civ 1161	Dkt. 126, Ex. B-13
106	<i>Belmont Park Investments Pty Ltd v BNY Corporate Trustee Services Ltd</i> [2011] UKSC 38	Dkt. 126, Ex. B-14
107	<i>Certain Ltd Partners in Henderson PFI Secondary Fund II LP v Henderson PFI Secondary Fund II LP</i> [2012] EWHC 3259 (Comm)	Dkt. 126, Ex. B-15
108	<i>Revenue and Customs Commissioners v Anson</i> [2013] EWCA Civ 63	Dkt. 126, Ex. B-16
109	<i>Re Pan Ocean Co Ltd</i> [2014] EWHC 2124 (Ch)	Dkt. 126, Ex. B-17
110	<i>Singularis Holdings v PricewaterhouseCoopers</i> [2014] UKPC 36	Dkt. 126, Ex. B-18
111	<i>MacDonald v Carnbroe Estates Ltd</i> [2019] UKSC 57	Dkt. 126, Ex. B-19
112	<i>Lau v Chu</i> [2020] UKPC 24	Dkt. 126, Ex. B-20

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
113	<i>Re Sova Capital Ltd [2023] EWHC 452 (Ch)</i>	Dkt. 126, Ex. B-21
114	<i>Mitchell v Al Jaber [2025] UKSC 43</i>	Dkt. 126, Ex. B-22
115	<i>Hopcraft v Close Brothers Ltd [2025] UKSC 33</i>	Dkt. 126, Ex. B-23
116	<i>Re Core VCT Plc [2025] EWHC 2316 (Ch)</i>	Dkt. 126, Ex. B-24
117	<i>Re Belmont Asset Based Lending Ltd [2010] CIGC J0121-2</i>	Dkt. 126, Ex. B-25
118	<i>In Re ICP Strategic Credit Income Fund Limited [2014] 1 CILR 314</i>	Dkt. 126, Ex. B-26
119	<i>Arnage Holdings Ltd v Walkers [2019] 2 CILR 382</i>	Dkt. 126, Ex. B-27
120	<i>In Re LATAM Finance Limited [2020] 2 CILR 787</i>	Dkt. 126, Ex. B-28
121	<i>In Re Duet Estate Partners LP [2020] (2) CILR 390</i>	Dkt. 126, Ex. B-29
122	<i>Tianrui (International) Holding Co Ltd v China Shanshui Cement Group Ltd [2020] 1 CILR 417</i>	Dkt. 126, Ex. B-30
123	<i>Re Padma Fund LP [2021] (2) CILR 556</i>	Dkt. 126, Ex. B-31
124	<i>Re Aquapoint LP FSD 157 of 2021 (DDJ), KY 2022 GC 69</i>	Dkt. 126, Ex. B-32
125	<i>Re Formation Group (Cayman) Fund I LP [2022] (1) CILR 594</i>	Dkt. 126, Ex. B-33
126	<i>Re Aquapoint LP, CICA (Civil) Appeal No. 0014 of 2022</i>	Dkt. 126, Ex. B-34
127	<i>Re ECM Straits Fund I LP FSD 230 of 2022 (RPJ)</i>	Dkt. 126, Ex. B-35
128	<i>In Re Seahawk China Dynamic Fund KY 2022 GC 92</i>	Dkt. 126, Ex. B-36
129	<i>Kuwait Ports Authority v Port Link GP Limited [2023] (1) CILR 50</i>	Dkt. 126, Ex. B-37
130	<i>Re Rothenberg Ventures 2016 Feeder Fund LP KY 2024 GC 38</i>	Dkt. 126, Ex. B-38
131	<i>In Re One Thousand & One Voices Africa Fund I LP KY 2024 GC 62</i>	Dkt. 126, Ex. B-39
132	<i>Williams v Kuwait Ports Authority CICA (Civil) Appeal No 0011 of 2023</i>	Dkt. 126, Ex. B-40

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
133	<i>Kuwait Ports Authority v Williams</i> [2024] UKPC 32	Dkt. 126, Ex. B-41
134	<i>Abraaj General Partner VIII Ltd v Abraaj ABOF IV SPV Ltd</i> [2025] CICA (Civ) 8	Dkt. 126, Ex. B-42
135	<i>Aquapoint LP v Xiaohu Fan</i> [2025] UKPC 56	Dkt. 126, Ex. B-44
136	<i>In Re One Thousand & One Voices Africa Fund I LP</i> [2025] CICA (Civ) 9	Dkt. 126, Ex. B-45
137	Goode on Principles of Corporate Insolvency Law, 5th Ed. (¶¶ 6-41; 7-29)	Dkt. 126, Ex. B-46
138	Lewin on Trusts, 20th Ed. (¶ 41-002)	Dkt. 126, Ex. B-47
139	Lightman & Moss on The Law of Administrators and Receivers of Companies, 6th Ed. (¶ 8-002)	Dkt. 126, Ex. B-48
140	Lindley & Banks on Partnership, 21st Ed. (multiple specified paragraphs)	Dkt. 126, Ex. B-49
141	McPherson & Keay's Law of Company Liquidation, 5th Ed. (multiple specified paragraphs)	Dkt. 126, Ex. B-50
142	Rigmora LPs' DIP Proposal	
143	Email from S. Levinson to Debtors re: LPs' DIP Proposal, Feb. 13, 2026	
144	February 29, 2024 correspondence between P. Eisenberg, M. Mitchnick, P. Jardine, N. Turaga, regarding Seth slide draft 02282024,	ATP_00070885
145	March 6, 2024 correspondence FW from P. Eisenberg to himself FW: BD teaser	ATP_00068479
146	April 6, 2024 correspondence between P. Eisenberg and V. Rusu Re: has Red Queen had any BD or financing discussions? Thanks	ATP_00069061
147	July 8, 2024 correspondence between P. Eisenberg, M. Ehlers, M. Mitchnick & P. Da Silva Jardine Re: Red Queen	ATP_00068952
148	July 12, 2024 correspondence between P. Eisenberg M. Mitchnick & P. Da Silva Jardine Re: Re: for review: draft Red Queen launch press release	ATP_00068953
149	August 20, 2024 correspondence FW from P. Eisenberg to himself FW: Red Queen Update	ATP_00070258
150	August 22, 2024 correspondence between P. Eisenberg M. Mitchnick re: decks	ATP_00070278

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
151	April 10, 2025 Board of Directors Meeting Apertor Pharmaceuticals	ATPBK_00048659
152	August 15, 2025 Red Queen Therapeutics Innovation In Antiviral Therapy Presentation	ATPBK_00004868
153	September 7, 2025 correspondence between P. Da Silva Jardine & S. Harrison Re: Better Estimates	ATPBK_00010924
154	September 23, 2025 correspondence between P. Da Silva Jardine & P. Eisenberg	ATPBK_00041455
155	October 28, 2025 correspondence between P. Eisenberg & P. Da Silva Jardine	ATPBK_00041491
156	October 28, 2025 correspondence between P. Eisenberg & Z. Su	ATPBK_00041428
157	March 26, 2025 correspondence between M. Karson, M. Jacobson, S. Liras, A. Robert, J. Adoudna, and T. Anjakortemme regarding ApoL1 position	ATP_00137366
158	November 26, 2024 correspondence between M. Karson, S. Liras, M. Jacobson regarding board presentation,	ATP_00139760
159	May 30, 2025 correspondence between L. Spiros, J. Yanchik, M. Karson, J. Leibowitz,	ATPBK_00000825
160	August 26, 2025 correspondence between M. Karson, L. Spiros, M. Arad, A. Lizotte,	ATPBK_00045728
161	Evercrisp Secured Promissory Note, June 11, 2025	
162	Evercrisp Management Update Deck, Dec. 9, 2025	ATPBK_00048699
163	Correspondence between Bogdanov and Harrison (June 11, 2025)	ATPBK_00038495 (and family)
164	Debtors R&Os to Rigmora LPs' Second Set of RFPs/Rogs	
165	B. Riley Draft Engagement Letter, Dec. 6 2025	ATPBK_00034992 (and family)
166	Demonstrative – Interrogatory 8 Response	
167	Email from D. Kaprow to Quinn Emanuel attaching proposed form of order, Dec. 8, 2025	RIGMORA_BK000001 43 (and family)
168	Email correspondence between D. Kaprow and A. Berdon re: proposed form of order, Dec. 9, 2025	RIGMORA_BK000001 48 (and family)

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
169	Demonstrative – reported commitments	
170	March 2025 SPV Deck	ATPBK_00018226
171	October 2025 Portfolio Lift Out Deck	ATP_00480811
172	Investor Outreach Spreadsheet	ATP_00480812
173	Correspondence between S. Harrison and A. Hack, July 2025	ATPBK_00023442
174	Correspondence between S. Harrison and P. Machir, August 2025	ATPBK_00027560
175	Correspondence between S. Harrison and EQT Partners, October 2025	ATPBK_00005921
176	Correspondence between S. Harrison and T. Hirsch, October 2025	ATPBK_00005983
177	Correspondence between S. Harrison and T. Hirsch, October 2025	ATPBK_00005624
178	Notice of Deposition of P. Mandarino	
179	B. Riley Engagement Letter, Dec. 9, 2025	
180	Correspondence between P. Mandarino and B. Riley, December 2025	ATPBK_00035051
181	Debtors' Responses & Objections to LPs' Second Set of RFPs and Interrogatories (Feb. 2, 2026)	
182	Cayman Second Witness Statement of Dr. Seth L Harrison, 8 Dec. 2025 (Trial Statement)	
183	Debtors' Omnibus Reply ISO Quinn and B. Riley Retentions, 13 Feb. 2026	
184	Declaration of Perry M. Mandarino ISO First Day Motion	Doc. 25
185	Aethon Therapeutics, Inc. Series A Preferred Stock Purchase Agreement, 16 Dec. 2022	ATP_00000546
186	Apertor Pharmaceuticals, Inc. Series A Preferred Stock Purchase Agreement, 5 Nov. 2020	ATP_00000596
187	Debtors' Supplemental Responses And Objections, 9 Feb. 2026	

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
188	ATP Life Science Ventures, L.P. Consolidated Financial Statements, 31 Dec. 2024	ATP_00000253
189	Aethon Therapeutics Valuation, 31 Dec. 2024	ATP_00359470
190	Marlinspike Therapeutics Valuation 31 Dec. 2024	WM_002963
191	Amendment 8 to LPA (Amending Management Agreement)	
192	Apple Tree Partners IV, L.P. – Amendment No. 14 16 Jan. 2026	Dkt. 160-5
193	ATP Life Science Ventures, L.P. - Amendment No. 20	ATP_00260368
194	Rigmora’s DIP Term Sheet	
195	Debtor’s DIP Funding Motion, 13 Feb. 2026	DKt. 313
196	Mandarino Deposition Transcript, 1 Jan. 2026	
197	Second Affirmation of Yuri Bogdanov	
198	2025-07-24 Plaintiff’s Notice of 30(b)(6) Deposition - Schedule A	
199	Writ - First Affidavit of Yuri Bogdanov	
200	Email from LPs to GP attaching Proposed Chancery Order, Dec. 8, 2025	
201	December Emails between LPs and GP re Proposed Chancery Order and Payment	
202	LPs Proposed Chancery Order, Dec. 10, 2025	
203	GP Proposed Chancery Order, Dec. 10, 2025	
204	Gulf Investment Corp v The Port Fund LP FSD 235 of 2019 and 13 of 2020, 19 June 2020	
205	Letter Decision Resolving Plaintiffs Exceptions, Sept. 8, 2025	
206	January Emails between LPs and Debtors re Document Production	
207	Email from P. Mandarino to B. Riley, Dec. 8, 2025	ATPBK_00035018

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
208	Intergalactic Chapter 11 Petition, Dec. 19, 2023	
209	2025.09.22 First Affirmation of Patrik Blochlinger	(FSD 151 of 2025) (sealed)
210	2025.12.05 Witness Statement of Yuri Bogdanov	
211	Grant Thornton 2024 Audited Financials	ATP_00089374
212	October Portfolio Lift-Out Opportunity Deck	ATP_00480812
213	2026.02.12 Rigmora DIP Objection	[360] SEALED
214	2026.02.18 Aegersold Dec ISO of DIP Objection	[363]
215	2026.02.18 Strebulaev Declaration	[365] SEALED
216	2026.02.18 Rimm Declaration	[366] SEALED
217	2026.02.18 Amended Aegersold Declaration	[369]
218	Blue Torch Capital Term Sheet	ATPBK_00052101
219	Burford Capital Term Sheet	ATPBK_00052045
220	Cover Email	Ex. A
221	Project Newton - 26 Week Cashflow - 2026.01.28 vF	Ex. C
222	JMB Capital Partners Lending Term Sheet	
223	Omni Bridgeway Term Sheet	ATPBK_00052050
224	Sandton Capital Partners Term Sheet	ATPBK_00052135
225	First Affirmation of Patrik Blochlinger.p	
226	Witness Statement of Yuri Bogdanov	
227	ATP Life Science Ventures, L.P. Pool V-3 Summary - Ezbon International Ltd. 12/31/2024	ATP_00089527

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
228	ATP Life Science Ventures, LP First Quarter 2022 Report As of March 31, 2022	ATP_00113187
229	ATP Life Science Ventures, LP Third Quarter 2023 Report As of September 30, 2023	ATP_00022719
230	Chancery Court Transcript Day 1	
231	ATP Life Science Ventures, LP First Quarter 2025 Report As of March 31, 2025	ATP_00004667
232	ATP Life Science Ventures, LP Fourth Quarter 2024 Report As of December 31, 2024	ATP_00004868
233	ATP Life Science Ventures LP Net IRR Calculation - Capital contributions and distributions by equity holders (Excludes Carry and ICU distributions) As of 12/3	ATP_00264756
234	2026.01.28 Project Newton - 26 Week Cashflow	
235	Aethon Investment Memorandum	ATP_00028117
236	Company & Program Table	ATP_00119573
237	2026.01.29 Project Newton - Portco Detail	
238	Q1 2025 Quarterly Digest.pdf	ATP0000466
239	Apertor Investment Memorandum.pdf	ATP00296730
240	ATP Portfolio Lift-Out Opportunities (Dec 2025)	
241	Evercrisp Investment Memorandum	ATP00122237
242	ATP Value Model for Portfolio Lift-Out	
243	Evercrisp Board Update (June 9, 2025)	ATPBK_00000996
244	Nereid, Nine Square, Opal (Initial) Investment Memoranda	ATP_00065989
245	Marlinspike Investment Memorandum	ATP_00233219
246	ATP Life Science Ventures, L.P. Consolidated Statement March 31, 2022	ATP_00012073

EXHIBIT	DESCRIPTION	DOCKET NO. / BATES NO. / OTHER IDENTIFIER
247	2024.03.07 Email Re Capital Calls for RQ	ATP_00125491
248	ATP Life Science Ventures Consolidated Financial Statement (Dec 2021)	ATP_00000030
249	Red Queen Investment Materials	ATP_00028524
250	Amended Notice of Deposition of Perry M. Mandarino	
251	Declaration of P. Mandarino December 23rd, 2025	
252	Debtors' Reply to Limited Omnibus Objection of Rigmora Biotech Investor to the Funding Motion	
253	Project Newton 13-Week Cash Flow	
254	2025.08.26 Michael Ehlers Deposition Transcript	
255	2026.02.18 (HIGHLY CONFIDENTIAL) Paul Da Silva Jardine Deposition Transcript	
256	2026.02.18 Nathaniel Wang Rough Deposition Transcript	
257	2026.02.18 Perry Mandarino Rough Deposition Transcript	
258	2026.02.18 Spiros Liras Rough Deposition Transcript	
259	Rigmora LPs Deposition Designations for 2.19.26 Hearing	
260	Mandarino Dec ISO Second Funding Motion	Dkt. 229
261	2025.12.09 GP Fund Petition	Dkt. 1
262	2024 ATP LSV Financial Statements	ATP_00000253

Dated: February 19, 2026
Wilmington, Delaware

**RICHARDS, LAYTON &
FINGER, P.A.**

/s/ Michael J. Merchant

John H. Knight (No. 3848)
Michael J. Merchant (No. 3854)
Daniel E. Kaprow (No. 6295)
Clint M. Carlisle (No. 7313)
Nicholas A. Franchi (No. 7401)
One Rodney Square
920 North King Street
Wilmington, DE 19801
Telephone: (302) 651-7700
Facsimile: (302) 651-7701
Email: knight@rlf.com
merchant@rlf.com
kaprow@rlf.com
carlisle@rlf.com
franchi@rlf.com

Respectfully Submitted,

DEBEVOISE & PLIMPTON LLP

Shannon Rose Selden (admitted *pro hac vice*)
M. Natasha Labovitz (admitted *pro hac vice*)
William H. Taft V (admitted *pro hac vice*)
Zachary H. Saltzman (admitted *pro hac vice*)
Natascha Born (admitted *pro hac vice*)
Carl Micarelli (admitted *pro hac vice*)
Sebastian Dutz (admitted *pro hac vice*)
66 Hudson Boulevard
New York, New York 10001
Telephone: (212) 909-6000
Email: srselden@debevoise.com
nlabovitz@debevoise.com
whtaft@debevoise.com
zsaltzman@debevoise.com
nborn@debevoise.com
cmicarelli@debevoise.com
spdutz@debevoise.com

*Counsel for Rigmora Biotech Investor One LP
(by and through its general partner Unicorn
Biotech Ventures One Ltd) and Rigmora Biotech
Investor Two LP (by and through its general
partner Unicorn Biotech Ventures Two Ltd)*